- Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge | NEJM nejm.org
- LI medical experts question Paxlovid study on symptoms in people under 65 Newsday
- Study finds Pfizer's antiviral has little or even zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week MarketWatch
- Paxlovid: Study finds no benefit in Pfizer Covid pill for younger adults syracuse.com
- Pfizer’s Paxlovid Excels at Treating Over 65s, Large Israeli Study Finds - Israel News Haaretz
from World - Latest - Google News https://ift.tt/kNb1inf
Comments
Post a Comment